R Soll
Overview
Explore the profile of R Soll including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hay S, Kirpalani H, Viner C, Soll R, Dukhovny D, Mao W, et al.
J Perinatol
. 2017 Sep;
37(11):1215-1219.
PMID: 28880258
Objective: To assess the impact of the latest randomized controlled trial (RCT) to each systematic review (SR) in Cochrane Neonatal Reviews. Study Design: We selected meta-analyses reporting the typical point...
2.
Al-Hosni M, Duenas M, Hawk M, Stewart L, Borghese R, Cahoon M, et al.
J Perinatol
. 2011 May;
32(4):253-9.
PMID: 21546942
Objective: The objective of this trial was to test whether probiotic-supplemented feeding to extremely low-birth-weight (ELBW) infants will improve growth as determined by decreasing the percentage of infants with weight...
3.
Pardanani A, Hood J, Lasho T, Levine R, Martin M, Noronha G, et al.
Leukemia
. 2007 Jun;
21(8):1658-68.
PMID: 17541402
JAK2V617F and MPLW515L/K represent recently identified mutations in myeloproliferative disorders (MPD) that cause dysregulated JAK-STAT signaling, which is implicated in MPD pathogenesis. We developed TG101209, an orally bioavailable small molecule...
4.
Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Hood J, Soll R
Biochem Soc Trans
. 2007 Mar;
35(Pt 2):204-6.
PMID: 17371238
In the present paper, we review the preclinical development of TG100-115, a PI3K (phosphoinositide 3-kinase) gamma/delta isoform-specific inhibitor currently in clinical trials for the reduction of acute MI (myocardial infarction)....
5.
Demuth C, Zerbe O, Rognan D, Soll R, Beck-Sickinger A, Folkers G, et al.
Biosens Bioelectron
. 2001 Oct;
16(9-12):783-9.
PMID: 11679256
Oligopeptides that interact with oxoanions were developed by rational design methods. The substrate-binding site of the enzyme purine nucleoside phosphorylase served as a model for the design of the ionophores....
6.
Subasinghe N, Illig C, Hoffman J, Rudolph M, Wilson K, Soll R, et al.
Bioorg Med Chem Lett
. 2001 May;
11(11):1379-82.
PMID: 11378359
The serine protease urokinase plasminogen activator (uPA) is thought to play a central role in tumor metastasis and angiogenesis. Molecular modeling studies suggest that 5-thiomethylthiopheneamidine inhibits uPA by binding at...
7.
Wilson K, Illig C, Subasinghe N, Hoffman J, Rudolph M, Soll R, et al.
Bioorg Med Chem Lett
. 2001 Apr;
11(7):915-8.
PMID: 11294390
The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino-1,3-thiazolyl]-thiophene-2-carboxamidines is...
8.
Berglund M, Lundell I, Eriksson H, Soll R, Beck-Sickinger A, Larhammar D
Peptides
. 2001 Apr;
22(3):351-6.
PMID: 11287089
The neuropeptide Y-family receptor Y4 differs extensively between human and rat in sequence, receptor binding, and anatomical distribution. We have investigated the differences in binding profile between the cloned human,...
9.
Soll R, Beck-Sickinger A
J Pept Sci
. 2000 Sep;
6(8):387-97.
PMID: 10969868
An efficient strategy for the synthesis of orexin A, a recently discovered neuropeptide with two intramolecular disulphide bonds, was developed. Four different methods for the synthesis of peptides containing two...
10.